UCB (OTCMKTS:UCBJF) Sees Strong Trading Volume – What’s Next?

UCB SA (OTCMKTS:UCBJF) shares saw unusually-high trading volume on Thursday . Approximately 5,553 shares traded hands during mid-day trading, an increase of 447% from the previous session’s volume of 1,015 shares.The stock last traded at $271.71 and had previously closed at $268.39.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on UCBJF shares. Morgan Stanley reiterated an “overweight” rating on shares of UCB in a report on Monday, September 8th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a research note on Monday, October 6th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy”.

UCB Stock Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm has a fifty day moving average of $272.95 and a 200-day moving average of $228.14.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.